Physician profile
William Koble
NPI 1558367102
$2,014.07
in general payments reported to CMS, 2019-2025
22 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $145 · 2021: $19.09 · 2022: $21.81 · 2023: $228 · 2024: $522 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $340.38 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $305.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $223.84 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $211.57 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $173.39 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $138.64 | 2019-2024 | |
| Amgen INC. | $77.78 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $66.89 | 2019 | |
| Alk-Abello, INC | $62.56 | 2025 | Odactra, Grastek, Ragwitek |
| Axsome Therapeutics, INC. | $58.78 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $54.62 | 2019 | |
| Dexcom, INC. | $54.48 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $42.10 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.51 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $27.75 | 2024 | Spinraza |
| Actelion Pharmaceuticals US, INC. | $23.44 | 2023 | Uptravi, Opsumit |
| Allergan, INC. | $23.16 | 2019 | |
| Abbvie INC. | $21.90 | 2024 | |
| Merck Sharp & Dohme LLC | $16.88 | 2019 | |
| Amarin Pharma, INC. | $14.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Koble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.